We had the pleasure of meeting with Chia-Chun Chiang (Mayo Clinic, Rochester, MN, USA) to discuss a real world study of ubrogepant in participants with acute migraine.
The abstract entitled: ‘Real World Efficacy, Tolerability and Safety of Ubrogepant’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- What is the current role of gepants in the treatment armamentarium for migraine? (0:30)
- What have clinical studies taught us about the efficacy and safety of ubrogepant? (1:57)
- Could you tell us a little about your real world study and its findings? (3:33)
- What factors were found to predict a good response to ubrogepant? (5:35)
Disclosures: Chia-Chun Chiang has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
